Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H28NO4.Br |
| Molecular Weight | 438.355 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].C[N@+]2(CC1CC1)[C@H]3C[C@@H](C[C@@H]2[C@H]4O[C@@H]34)OC(=O)[C@H](CO)C5=CC=CC=C5
InChI
InChIKey=WDURTRGFUGAJHA-GSWUYBTGSA-M
InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15-,16-,17-,18+,19-,20+,22?;/m1./s1
| Molecular Formula | C21H27NO4 |
| Molecular Weight | 357.4434 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3912339
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3912339
Cimetropium bromide (cimetropium) is a semi-synthetic belladonna alkaliod, a quaternary
derivatives of scopolamine. Cimetropium was used in Italy under the name Alginor for the treatment of painful gastrointestinal conditions, such as irritant bowel syndrome or infant colics as well as in preparation for diagnostic procedures. The drug exerts its action by binding to muscarinic receptors and inhibiting their activity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3912339 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ALGINOR Approved UseIrritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions. |
|||
| Primary | ALGINOR Approved UseIrritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions. |
|||
| Primary | ALGINOR Approved UseIrritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions. |
|||
| Diagnostic | ALGINOR Approved UseIrritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3761170/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.39 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16810649/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
22.68 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16810649/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3761170/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
119 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3761170/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16810649/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIMETROPIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 mg 3 times / day steady-state, oral Studied dose Dose: 50 mg, 3 times / day Route: oral Route: steady-state Dose: 50 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: dry mouth... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| dry mouth | 6 patients | 50 mg 3 times / day steady-state, oral Studied dose Dose: 50 mg, 3 times / day Route: oral Route: steady-state Dose: 50 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison between the Effectiveness of Oral Phloroglucin and Cimetropium Bromide as Premedication for Diagnostic Esophagogastroduodenoscopy: An Open-Label, Randomized, Comparative Study. | 2015-01 |
|
| Looking for new treatments of Infantile Colic. | 2014-06-05 |
|
| [Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group]. | 1997-07 |
|
| Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. | 1990-03 |
Patents
Sample Use Guides
Solution for injection: 1 vial (equivalent to 5 mg of cimetropium bromide) given intravenously or intramuscularly in the onset of painful spastic crisis. The injection can be repeated in the event of pain relapse even 3-4 times a day (spastic-painful manifestations of the gastrointestinal tract); 2 ampoules (equivalent to 10 mg of cimetropium bromide) given intravenously (preparation for instrumental investigations). Tablets: 1 tablet (equivalent to 50 mg of cimetropium bromide) 2-3 times daily in adults. Oral solution: 20 drops (equivalent to 50 mg of cimetropium bromide) 3 times per day in adults and 3-5 drops (equivalent to 1.2-2 mg of cimetropium bromide) per kg of weight 4-6 times per day in children.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9127842
Longitudinal muscle preparations with myenteric plexus of guinea-pig ileum were treated with 0.1, 1, 10 uM cimetropium. The drug caused inhibition of contraction of the preparations, induced by exogenous ACh or electrical field stimulation. pA2 value was determined to be 7.96.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:43:23 GMT 2025
by
admin
on
Wed Apr 02 09:43:23 GMT 2025
|
| Record UNII |
0C7M5WE60Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
||
|
WHO-VATC |
QA03BB05
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
||
|
WHO-ATC |
A03BB05
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5478
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
C90696
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
51598-60-8
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
100000092023
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
DBSALT001931
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
0C7M5WE60Q
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
m3553
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | Merck Index | ||
|
CIMETROPIUM BROMIDE
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110773
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
SUB06280MIG
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY | |||
|
DTXSID10965919
Created by
admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |